Entero Therapeutics (ENTO)

• Market cap: $9.02M
• 1 day: -4.06%
• 5 days: 4.42%
• 1 month: -15%
• 3 months: 221.97%
• 6 months: 316.67%
• Year to date: 119.07%
• 1 year: 121.35%
• 5 years: -100%
• 10 years: -100%
• Sector: Healthcare
• Industry: Biotechnology

About: Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Employees: 2